The stock of Bone Biologics Corp (BBLG) has gone down by -4.06% for the week, with a -4.62% drop in the past month and a 48.66% rise in the past quarter. The volatility ratio for the week is 8.03%, and the volatility levels for the past 30 days are 20.79% for BBLG. The simple moving average for the last 20 days is -13.02% for BBLG stock, with a simple moving average of -22.11% for the last 200 days.
Is It Worth Investing in Bone Biologics Corp (NASDAQ: BBLG) Right Now?
Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BBLG is 0.52M, and at present, short sellers hold a 67.82% of that float. On October 16, 2024, the average trading volume of BBLG was 4.90M shares.
BBLG) stock’s latest price update
Bone Biologics Corp (NASDAQ: BBLG) has seen a rise in its stock price by 11.49 in relation to its previous close of 1.48. However, the company has experienced a -4.06% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-08-02 that BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exerc.
BBLG Trading at 1.50% from the 50-Day Moving Average
After a stumble in the market that brought BBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.37% of loss for the given period.
Volatility was left at 20.79%, however, over the last 30 days, the volatility rate increased by 8.03%, as shares sank -17.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.48% lower at present.
During the last 5 trading sessions, BBLG remain unchanged, which changed the moving average for the period of 200-days by -61.95% in comparison to the 20-day moving average, which settled at $1.9005. In addition, Bone Biologics Corp saw -63.49% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BBLG
The total capital return value is set at -1.7. Equity return is now at value -119.03, with -94.66 for asset returns.
Currently, EBITDA for the company is 0.48 million with net debt to EBITDA at 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.22.
Conclusion
To sum up, Bone Biologics Corp (BBLG) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
